Vincent C. Tam

6.8k total citations · 3 hit papers
64 papers, 2.7k citations indexed

About

Vincent C. Tam is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vincent C. Tam has authored 64 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hepatology, 28 papers in Oncology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vincent C. Tam's work include Hepatocellular Carcinoma Treatment and Prognosis (31 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers). Vincent C. Tam is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (31 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers). Vincent C. Tam collaborates with scholars based in Canada, United States and Italy. Vincent C. Tam's co-authors include Edward Etchells, Patricia Cornish, Romina Marchesano, Simon R. Knowles, David N. Juurlink, Steven Shadowitz, George Varghese, Zhidong Xie, Susan R. George and Roderick Tse and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Vincent C. Tam

61 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unintended Medication Discrepancies at the Time of Hospital Admission

2005 719 citations Patricia Cornish, Simon R. Knowles et al. Archives of Internal Medicine profile →
Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review

2005 614 citations Vincent C. Tam Canadian Medical Association Journal profile →
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology profile →

Peers

Vincent C. Tam

EMS

HEPAT

ONCOL

Frank G. A. Jansman Netherlands

Rachel P. Riechelmann Brazil

Robert A. Hamilton United States

Matthijs L. Becker Netherlands

Morten Hansen Denmark

Allen Brinker United States

Jung Mi Oh South Korea

Kate Traynor United States

Nikki M. Carroll United States

Ghada Miremont‐Salamé France

Frank G. A. Jansman Netherlands

Vincent C. Tam

334 ×0.3

113 ×0.1

EMS

316 ×0.6

33 ×0.1

HEPAT

668 ×1.6

ONCOL

Citations per year, relative to Vincent C. Tam Vincent C. Tam (= 1×) peers Frank G. A. Jansman

Countries citing papers authored by Vincent C. Tam

Since Specialization

Citations

This map shows the geographic impact of Vincent C. Tam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent C. Tam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent C. Tam more than expected).

Fields of papers citing papers by Vincent C. Tam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent C. Tam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent C. Tam. The network helps show where Vincent C. Tam may publish in the future.

Co-authorship network of co-authors of Vincent C. Tam

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent C. Tam. A scholar is included among the top collaborators of Vincent C. Tam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent C. Tam. Vincent C. Tam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freeman, M. E., Ravi Ramjeesingh, Jessica Li, et al.. (2024). Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium.. Journal of Clinical Oncology. 42(16_suppl). 4098–4098. 1 indexed citations

Reig, María, Vincent C. Tam, Isabelle Archambeaud, et al.. (2024). 167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 35. S75–S76. 1 indexed citations

Ramjeesingh, Ravi, Prosanto Chaudhury, Vincent C. Tam, et al.. (2023). A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada. Current Oncology. 30(8). 7132–7150. 8 indexed citations

Freeman, M. E., Conor O’Donnell, Brandon M. Meyers, et al.. (2023). Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.. Journal of Clinical Oncology. 41(16_suppl). 4105–4105. 1 indexed citations

Meyers, Brandon M., Jennifer J. Knox, David Liu, et al.. (2023). The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review. Cancer Treatment Reviews. 118. 102584–102584. 13 indexed citations

Sangro, Bruno, George Lau, Masatoshi Kudo, et al.. (2023). 147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 34. S1530–S1531. 1 indexed citations

Howell, Jessica, Vincent C. Tam, Dominik Bettinger, et al.. (2022). Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances in Gastroenterology. 15. 1098283082–1098283082. 18 indexed citations

Doherty, Mark, Vincent C. Tam, Mairéad G. McNamara, et al.. (2022). Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British Journal of Cancer. 127(8). 1473–1478. 7 indexed citations

Allen, Michael J., Jennifer J. Knox, Erica S. Tsang, et al.. (2021). Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD).. Journal of Clinical Oncology. 39(3_suppl). 275–275. 3 indexed citations

10.

Busset, Michele Droz Dit, Walid L. Shaib, Kabir Mody, et al.. (2021). 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01. Annals of Oncology. 32. S376–S376. 14 indexed citations

11.

Kelley, Robin Kate, Tim Meyer, Lorenza Rimassa, et al.. (2020). Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 26(18). 4795–4804. 66 indexed citations

12.

Lee‐Ying, Richard M., Hao‐Wen Sim, Kelvin Chan, et al.. (2020). Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database. Cancer Medicine. 9(14). 4918–4928. 11 indexed citations

13.

Tam, Vincent C., et al.. (2020). Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Current Oncology. 27(13). 173–180. 6 indexed citations

14.

Bonner, Ann, et al.. (2020). A multimorbidity nurse practitioner-led clinic: Evaluation of health outcomes. Collegian Journal of the Royal College of Nursing Australia. 27(4). 430–436. 13 indexed citations

15.

Tam, Vincent C., Paris‐Ann Ingledew, Scott Berry, Sunil Verma, & Meredith Giuliani. (2016). Developing Canadian oncology education goals and objectives for medical students: a national modified Delphi study. CMAJ Open. 4(3). E359–E364. 6 indexed citations

16.

Quik, Maryka, Joan Holgate, Michael Morgan, et al.. (2016). Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake. PLoS ONE. 11(3). e0150270–e0150270. 31 indexed citations

17.

Tam, Vincent C., et al.. (2013). Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer. Current Oncology. 20(2). 90–106. 59 indexed citations

18.

Cornish, Patricia, Simon R. Knowles, Romina Marchesano, et al.. (2005). Unintended Medication Discrepancies at the Time of Hospital Admission. Archives of Internal Medicine. 165(4). 424–424. 719 indexed citations breakdown →

19.

Tam, Vincent C.. (2005). Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. Canadian Medical Association Journal. 173(5). 510–515. 614 indexed citations breakdown →

20.

George, Susan R., Theresa Fan, Zhidong Xie, et al.. (2000). Oligomerization of μ- and δ-Opioid Receptors. Journal of Biological Chemistry. 275(34). 26128–26135. 464 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact